Anonymous
Guest
Anonymous
Guest
From Heartwire
US Bleeding ADRs Higher With Dabigatran Than Warfarin
Sue Hughes
January 12, 2012 (Horsham, Pennsylvania) — Concerns about bleeding with dabigatran (Pradaxa, Boehringer Ingelheim) continue, with a new report that adverse drug reactions (ADRs) involving hemorrhage reported to the US FDA were higher for the new oral anticoagulant than for warfarin in the first quarter of 2011 [1]. Many of the bleeding events with dabigatran involved intracranial hemorrhage in elderly patients.
The report is from QuarterWatch, a program from the Institute of Safe Medication Practices that monitors all serious, disabling, and fatal adverse drug events reported to the FDA through its MedWatch reporting program.
The latest data show that there were 505 reports of hemorrhage with dabigatran in the first quarter of 2011, which QuarterWatch says is "more than any other monitored drug, including warfarin, which ranked second, with 176 cases of hemorrhage."
US Bleeding ADRs Higher With Dabigatran Than Warfarin
Sue Hughes
January 12, 2012 (Horsham, Pennsylvania) — Concerns about bleeding with dabigatran (Pradaxa, Boehringer Ingelheim) continue, with a new report that adverse drug reactions (ADRs) involving hemorrhage reported to the US FDA were higher for the new oral anticoagulant than for warfarin in the first quarter of 2011 [1]. Many of the bleeding events with dabigatran involved intracranial hemorrhage in elderly patients.
The report is from QuarterWatch, a program from the Institute of Safe Medication Practices that monitors all serious, disabling, and fatal adverse drug events reported to the FDA through its MedWatch reporting program.
The latest data show that there were 505 reports of hemorrhage with dabigatran in the first quarter of 2011, which QuarterWatch says is "more than any other monitored drug, including warfarin, which ranked second, with 176 cases of hemorrhage."